Liver metastases are the key determinant of overall survival in metastatic uveal melanoma.1
Recent data from the FOCUS study shows that more than 1/3 of patients responded to treatment with Chemosat (ORR reported in FOCUS was 36.3%, n = 33)2
Liver directed therapy is the recommended treatment approach for patients with hepatic dominant uveal melanoma, where resection is not possible.3,4
Liver metastases are the key determinant of overall survival in metastatic uveal melanoma.1
Recent data from the FOCUS study shows that more than 1/3 of patients responded to treatment with Chemosat (ORR reported in FOCUS was 36.3%, n = 33)2
Liver directed therapy is the recommended treatment approach for patients with hepatic dominant uveal melanoma, where resection is not possible.3,4
CHEMOSAT is a liver directed therapy with growing evidence to support its role as a standard of care in metastatic uveal melanoma.5-7
CHEMOSAT harnesses the tumour vascular supply by delivery of melphalan into the hepatic artery, which represents almost exclusively the arterial supply to liver tumours.5,8
CHEMOSAT achieves 10-fold higher peak perfusate drug concentration of melphalan to the liver than systemic administration while controlling systemic exposure and associated side effects.1
CHEMOSAT offers hope for patients suffering from metastatic uveal melanoma. Multiple published clinical studies have demonstrated that CHEMOSAT can meaningfully alter the course of disease and improve patients’ chances of survival. It is a real game changer in the treatment of metastatic uveal melanoma.
Delcath CEO,
Gerard Michel
Delcath are an interventional oncology company.
Delcath are the manufacturers of CHEMOSAT and have over 12 years' experience in the European market. We are committed to improving the lives of patients with primary and metastatic liver cancer. Our in-house clinical team continues to focus on areas such as metastatic uveal melanoma (mUM), intrahepatic cholangiocarcinoma (ICC) & colorectal cancer (CRC)
